Stephen Moses - Revision history

WikiModEn2: /* Active projects */ Wikify.

2024-07-08T13:57:00Z

Active projects: Wikify.

← Older revision		Revision as of 13:57, 8 July 2024
Line 115:		Line 115:
	* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>		* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
	* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Monitoring and evaluation of the Avahan project in [[India]].<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, [[India]].<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>		* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>

WikiModEn2: Add link in SEEALSO section.

2024-04-14T21:08:59Z

Add link in SEEALSO section.

← Older revision		Revision as of 21:08, 14 April 2024
Line 258:		Line 258:
	{{SEEALSO}}		{{SEEALSO}}
	* [[Bias]]		* [[Bias]]
			* [[Canada]]
	* [[Circumcised doctors]]		* [[Circumcised doctors]]

WikiModEn2: Add category.

2022-09-03T15:37:46Z

Add category.

← Older revision		Revision as of 15:37, 3 September 2022
Line 268:		Line 268:

	[[Category:Researcher]]		[[Category:Researcher]]
			[[Category:Author]]

	[[Category:Canada]]		[[Category:Canada]]

WikiAdmin: wikify DOC

2022-06-16T08:53:52Z

wikify DOC

← Older revision		Revision as of 08:53, 16 June 2022
Line 80:		Line 80:
	\|last=		\|last=
	\|first=		\|first=
	\|publisher=Doctors Opposing Circumcision		\|publisher=[[Doctors Opposing Circumcision (D.O.C.)]]
	\|date=2016		\|date=2016
	\|title=HIV/AIDS		\|title=HIV/AIDS

WikiAdmin: wikify Michel Garenne

2022-04-12T12:49:09Z

wikify Michel Garenne

← Older revision		Revision as of 12:49, 12 April 2022
Line 87:		Line 87:
	}}</ref>Of the three {{#tip-text:RCT\|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT\|Randomized controlled trial}} that was carried out in Kenya.<ref>{{RCT Bailey et al 2007}}</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.		}}</ref>Of the three {{#tip-text:RCT\|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT\|Randomized controlled trial}} that was carried out in Kenya.<ref>{{RCT Bailey et al 2007}}</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.

	Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal		Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> [[Michel Garenne\|Garenne]] & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal
	\|last=Garenne		\|last=Garenne
	\|init=M		\|init=M
	\|author-link=		\|author-link=Michel Garenne
	\|last2=Matthews		\|last2=Matthews
	\|init2=A		\|init2=A

WikiAdmin: using template:RCT Bailey et al 2007

2021-12-31T05:47:09Z

using template:RCT Bailey et al 2007

Show changes

WikiAdmin: using UNI template

2021-12-13T20:08:22Z

using UNI template

← Older revision		Revision as of 20:08, 13 December 2021
Line 70:		Line 70:
	\|title=Dr. Stephen Moses		\|title=Dr. Stephen Moses
	\|url=http://umanitoba.ca/faculties/medicine/units/medical_microbiology/faculty/StephenMoses.html		\|url=http://umanitoba.ca/faculties/medicine/units/medical_microbiology/faculty/StephenMoses.html
	\|publisher=University of Manitoba		\|publisher={{UNI\|University of Manitoba\|UManitoba}}
	\|date=		\|date=
	\|accessdate=2011-02-23		\|accessdate=2011-02-23

WikiAdmin: wikify HIV

2021-11-24T14:39:10Z

wikify HIV

← Older revision		Revision as of 14:39, 24 November 2021
Line 55:		Line 55:
	\|DOI=10.1111/j.1464-410X.2005.05810.x		\|DOI=10.1111/j.1464-410X.2005.05810.x
	\|accessdate=		\|accessdate=
	}}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an HIV prevention method.<ref>{{REFweb		}}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an [[HIV]] prevention method.<ref>{{REFweb
	\|last=World Health Organization		\|last=World Health Organization
	\|first=		\|first=
Line 65:		Line 65:

	== Interests ==		== Interests ==
	According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/HIV transmission.<ref name='moses-bio'>{{REFweb		According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/[[HIV]] transmission.<ref name='moses-bio'>{{REFweb
	\|last=Moses		\|last=Moses
	\|first=Stephen		\|first=Stephen
Line 85:		Line 85:
	\|url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/		\|url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/
	\|accessdate=2020-03-23		\|accessdate=2020-03-23
	}}</ref>Of the three {{#tip-text:RCT\|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as HIV prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT\|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.		}}</ref>Of the three {{#tip-text:RCT\|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT\|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.

	Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in HIV was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much HIV infection as intact men.<ref>{{REFjournal		Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal
	\|last=Garenne		\|last=Garenne
	\|init=M		\|init=M
Line 113:		Line 113:

	== Active projects ==		== Active projects ==
	* A randomized, controlled trial of male circumcision to reduce HIV incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>		* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
	* Scaling up HIV prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>		* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
	* Mapping key populations for HIV prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>		* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>

	== Recent publications ==		== Recent publications ==
Line 140:		Line 140:
	\|accessdate=		\|accessdate=
	}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey\|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small>		}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey\|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small>
	* Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.<ref>{{REFjournal		* Top Achievements in Health Research: Male circumcision: a new approach to reducing [[HIV]] transmission.<ref>{{REFjournal
	\|last=Moses		\|last=Moses
	\|init=S		\|init=S
Line 156:		Line 156:
	\|accessdate=		\|accessdate=
	}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small>		}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small>
	* Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal		* Does sex in the early period after circumcision increase [[HIV]]-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal
	\|last=Mehta		\|last=Mehta
	\|init=SD		\|init=SD
Line 177:		Line 177:
	}}		}}
	</ref><br><small>Mehta SD, '''[[Ronald Gray\|Gray RH]]''', '''[[Bertran Auvert\|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer\|Wawer MJ]]''', '''[[Robert C. Bailey\|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small>		</ref><br><small>Mehta SD, '''[[Ronald Gray\|Gray RH]]''', '''[[Bertran Auvert\|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer\|Wawer MJ]]''', '''[[Robert C. Bailey\|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small>
	* Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.<ref>{{REFjournal		* Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial.<ref>{{REFjournal
	\|last=Bailey		\|last=Bailey
	\|init=RC		\|init=RC
Line 198:		Line 198:
	}}		}}
	</ref><br><small>'''[[Robert C. Bailey\|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small>		</ref><br><small>'''[[Robert C. Bailey\|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small>
	* Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa.<ref>{{REFjournal		* Modelling the public health impact of male circumcision for [[HIV]] prevention in high prevalence areas in Africa.<ref>{{REFjournal
	\|last=Nagelkerke		\|last=Nagelkerke
	\|init=NJ		\|init=NJ

WikiAdmin: wikify 'uncircumcised'

2021-03-19T07:58:22Z

wikify 'uncircumcised'

← Older revision		Revision as of 07:58, 19 March 2021
Line 120:		Line 120:

	== Recent publications ==		== Recent publications ==
	* Prevalence and risk factors for human papillomavirus infection by penile site in uncircumcised Kenyan men.<ref>{{REFjournal		* Prevalence and risk factors for human papillomavirus infection by penile site in [[uncircumcised]] Kenyan men.<ref>{{REFjournal
	\|last=Smith		\|last=Smith
	\|init=JS		\|init=JS

WikiAdmin: using template BoyleGJ HillG 2011

2020-12-30T13:55:08Z

using template BoyleGJ HillG 2011

@@ Line 87: / Line 87: @@
 }}</ref>Of the three {{#tip-text:RCT|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as HIV prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.
-Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in HIV was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{REFjournal
+Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in HIV was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much HIV infection as intact men.<ref>{{REFjournal
   |last=Garenne
   |init=M